<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Luan F</submitter><funding>NIAID NIH HHS</funding><pagination>e202503335</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12559151</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>9(1)</volume><pubmed_abstract>T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2-expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when &lt;i>Bcl6&lt;/i> was knocked out upon T-cell activation. Glycolysis was promo</pubmed_abstract><journal>Life science alliance</journal><pubmed_title>Loss of &amp;lt;i&amp;gt;Bcl6&amp;lt;/i&amp;gt; promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function.</pubmed_title><pmcid>PMC12559151</pmcid><funding_grant_id>R01 AI137252</funding_grant_id><pubmed_authors>Blane TR</pubmed_authors><pubmed_authors>Luan F</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Tran JT</pubmed_authors><pubmed_authors>Huang Z</pubmed_authors><pubmed_authors>Nemazee D</pubmed_authors><pubmed_authors>Ning J</pubmed_authors><pubmed_authors>Bhargava R</pubmed_authors><pubmed_authors>Xiao C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Loss of &amp;lt;i&amp;gt;Bcl6&amp;lt;/i&amp;gt; promotes antitumor immunity by activating glycolysis to rescue CD8 T-cell function.</name><description>T cells are one of the most powerful weapons to fight cancer; however, T-cell exhaustion and dysfunction restrict their long-lasting function in antitumor immunity. B-cell lymphoma 6 (BCL6) has many functions in CD8 T cells; however, it is unclear how it regulates the effector function and exhaustion of CD8 cells. Overall, a low level of BCL6 mRNA in human cancer samples is associated with better outcomes, but high expression of BCL6 is specifically observed in cytotoxic CD8 T cells. We found that BCL6 deficiency in activated CD8 T cells enhanced tumor repression in multiple mouse models. More IL-2-expressing CD8 T cells and reduced proportions of exhausted or dysfunctional CD8 T cells were detected within tumors when &lt;i>Bcl6&lt;/i> was knocked out upon T-cell activation. Glycolysis was promo</description><dates><release>2026-01-01T00:00:00Z</release><publication>2026 Jan</publication><modification>2026-06-05T07:14:20.88Z</modification><creation>2026-05-14T03:09:10.433Z</creation></dates><accession>S-EPMC12559151</accession><cross_references><pubmed>41145211</pubmed><doi>10.26508/lsa.202503335</doi></cross_references></HashMap>